By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


miRagen Therapeutics 

6200 Lookout Road
Suite 100
Boulder  Colorado  80301  U.S.A.
Phone: 303-531-5952 Fax: 303-531-5094


Start Up

Company News
miRagen Presents New MRG-201 Preclinical Data For Inhaled Microrna-29 Mimic Targeting Pulmonary Fibrosis 9/12/2017 12:15:02 PM
miRagen Reports Second Quarter 2017 Financial Results And Provides Corporate Update 8/14/2017 8:41:51 AM
miRagen To Announce Second Quarter 2017 Financial Results And Host Webcast Conference Call On August 11, 2017 8/1/2017 1:21:13 PM
miRagen To Ring The Nasdaq Stock Market Closing Bell 7/21/2017 8:33:40 AM
miRagen To Present MRG-106 Phase I Clinical Trial Data At The International Conference On Malignant Lymphoma 6/8/2017 10:56:36 AM
miRagen Receives EU Orphan Medicinal Product Designation For MRG-106 For The Treatment Of Cutaneous T-Cell Lymphoma 5/24/2017 10:57:31 AM
miRagen To Present New Clinical Trial Data For MRG-106, An Oligonucleotide Therapeutic Targeting Microrna-155, At The ASCO Annual Meeting 5/18/2017 12:32:18 PM
miRagen Reports First Quarter 2017 Financial Results And Provides Corporate Update 5/11/2017 1:15:05 PM
miRagen To Host Conference Call Discussing First Quarter 2017 Corporate Update And Financial Results 5/3/2017 10:43:22 AM
Servier And miRagen Extend Collaboration For The Research, Development And Commercialization Of Microrna-Targeting Therapeutics 5/3/2017 10:26:45 AM